Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.
Recently, it was shown that interferon consensus sequence binding protein (ICSBP), a member of the interferon regulatory factor (IRF) family, has a potential role in chronic myeloid leukemia (CML). Deletion of ICSBP gene in mice leads to a CML-like syndrome and samples from CML patients exhibited impaired ICSBP expression. The present study found that ICSBP expression correlated with risk features determined by Sokal score in untreated CML (P =.007 for high versus low risk). In addition, analyzing ICSBP expression during interferon-alpha (IFN-alpha) therapy in "good" (n = 27) versus "poor" (n = 15) cytogenetic responders, high ICSBP levels were only observed in "good" responders (P =.0002). Together, these data suggest that ICSBP levels are related to initial presentation of CML and the therapeutic response of CML to IFN-alpha, indicating an important role of ICSBP in CML. (Blood. 2001;97:3648-3650)
Schmidt
M
M
Klinikum der Philipps-Universität Marburg, Zentrum Innere Medizin, Abteilung Hämatologie/Onkologie/Immunologie, Baldingerstrasse, 35043 Marburg, Germany.
Hochhaus
A
A
Nitsche
A
A
Hehlmann
R
R
Neubauer
A
A
D020732:Cytogenetic Analysis; D015870:Gene Expression; D006801:Humans; D050835:Interferon Regulatory Factors; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy; D012333:RNA, Messenger / Q000097:blood; D012097:Repressor Proteins / Q000097:blood / Q000235:genetics* / Q000502:physiology; D012189:Retrospective Studies; D012307:Risk Factors; D000099185:Interferon Regulatory Factor-8
D050835:Interferon Regulatory Factors; D016898:Interferon-alpha; D012333:RNA, Messenger; D012097:Repressor Proteins; D000099185:Interferon Regulatory Factor-8